Posted inNew Drugs, Oncology, Regulatory Tevimbra: Immuno-Oncologic Treatment for Esophageal Cancer March 19, 2024April 2, 2024 Tislelizumab for the treatment of unresectable or metastatic esophageal squamous cell carcinoma.
